Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease: A Factorial Mendelian Randomization Study.

ABSTRACT:

Importance

Cholesteryl ester transfer protein inhibition (CETP) has been shown to increase levels of high-density lipoprotein cholesterol (HDL-C) and reduce levels of low-density lipoprotein cholesterol (LDL-C). Current LDL-C target attainment is low, and novel phase 3 trials are underway to investigate whether CETP inhibitors result in reduction of cardiovascular disease risk in high-risk patients who may be treated with PCSK9-inhibiting agents.

Objective

To explore the associations of combined reduction of CETP and PCSK9 concentrations with risk of coronary artery disease (CAD) and other clinical and safety outcomes.

Design, setting, and participants

Two-sample 2 × 2 factorial Mendelian randomization study in a general population sample that includes data for UK Bio

SUBMITTER: Cupido AJ 

PROVIDER: S-EPMC9350849 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature